WuXi PharmaTech secures GLP certificate for Suzhou lab
Shanghai. November 10. INTERFAX-CHINA - WuXi PharmaTech (Cayman) Inc., China's largest contract research organization (CRO), has secured Good Laboratory Practice (GLP) certification from the State Food and Drug Administration (SFDA) for its toxicology facility in Suzhou City, Jiangsu Province, the company announced Nov. 8.
In September this year, WuXi PharmaTech received GLP certification for the same facility from the Organization for Economic Cooperation and Development (OECD), Interfax previously reported.
According to the announcement, the facility is now the only toxicology laboratory in China that has GLP certification from both the OECD and SFDA.
"This certification from the SFDA represents an important milestone in our efforts to offer clients toxicology studies that meet both domestic and international GLP standards for filing Investigational New Drugs (IND)," said Ge Li, chairman and CEO of WuXi PharmaTech in the statement.